In 1997, Takeda, the largest pharmaceutical company in Japan, established a Formulation Plant in Bray, Wicklow, for the manufacture of three of the company’s blockbuster drugs (Prevacid, Blopress and Actos). The establishment of this facility was paramount to Takeda’s strategy in responding to expanding growth in the European and US markets. This plant has significantly expanded its operation since inception and operates on a 24 hour/7 day basis.
In July 2009, Takeda officially opened its state-of-the-art Active Pharmaceuticals Ingredient (API) manufacturing facility at Grange Castle, Dublin. This facility will act as the launch vehicle for new strategic products for global markets, developing and producing API’s from clinical trial stages through to launch and full commercialisation.
The establishment of the Grange Castle facility was due to Takeda’s expanding sales in the European and US markets. Having examined various options, the company chose Ireland as the location for their first API facility outside of Japan. The output is supplied to the parent company and to the Bray facility for the manufacture of tablets and capsules.
Takeda currently employ approximately 400 people in Ireland and have invested over €250 million at their two Irish subsidiaries, Grange Castle in Dublin and at Bray in Co. Wicklow.
How Ireland Benefits Takeda
Convenient access to the EU and The US
Takeda’s presence in Ireland takes advantage of Ireland’s strategic geographical location and strong relationships with Europe and The United States.
Access to a highly skilled, well educated workforce
Strong Irish Government-backed investments in third and fourth-level education have resulted in a well educated workforce, along with access to a bank of highly skilled pharmaceutical professionals.
Ireland’s manufacturing skills have attracted many of the world’s largest pharmaceutical companies for the commercial production of ingredients and finished products.
Tax efficient structure
Takeda benefits from Ireland’s low corporate tax rate of 12.5%, along with grant assistance from the Irish Government.